Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$133.10

-0.35 (-0.26%)

10:53
10/07/16
10/07
10:53
10/07/16
10:53

Goldman says marijuana-derived drug maker GW Pharma 'set to fly high'

In a note to investors this morning, Goldman Sachs analyst Salveen Richter initiated GW Pharmaceuticals (GWPH) with a Buy rating, as he expects a "solid" launch trajectory for the company's lead asset Epidiolex. Earlier this week, his peer at Leerink resumed coverage of the stock with a Buy-equivalent rating, citing also the potential uptake trajectory of its investigational drug. BACKGROUND: GW Pharmaceuticals is a pre-commercial-stage biopharmaceutical company focused on cannabis-based therapies in central nervous system disorders. Its lead asset is Epidiolex for Dravet Syndrome and Lennox-Gastaut Syndrome, two severe orphan epilepsies. 'SOLID' LAUNCH, UPCOMING CATALYSTS: Goldman Sachs' Richter initiated coverage of GW Pharmaceuticals with a Buy rating, saying it is "set to fly high." The analyst told investors that he expects a "solid" launch trajectory for the company's lead asset Epidiolex, and is modeling $1.6B in world-wide sales. Further, Richter sees GW Pharmaceuticals' shares trading higher on upcoming pipeline catalysts, including the publication of Epidiolex Phase 3 study data in Dravet syndrome in a top-tier medical journal in the fourth quarter, the American Epilepsy Society meeting, and the initiation of an Epidiolex Phase 3 study in infantile spasms in the fourth quarter, among a number of other events. GW Pharmaceuticals should submit the U.S. regulatory filing for Epidiolex in Dravet Syndrome and Lennox-Gastaut Syndrome in the first half of 2017, he noted, adding that he expects U.S. and EU launches in the second or third quarter of 2018. The analyst has a $189 price target on the shares. UPTAKE DRUG TRAJECTORY: On Tuesday, Leerink analyst Paul Matteis resumed coverage of GW Pharmaceuticals with an Outperform rating and $162 price target, saying he is "highly positive" on the potential uptake trajectory of Epidiolex, now that its approval appears mostly de-risked after three successful Phase 3 trials in Dravet Syndrome and Lennox Gastaut. Moreover, the analyst sees multiple points of optimism regarding a GW Pharmaceuticals-led global launch, including strong clinical profile and "hype" surrounding Epidiolex, significant level of unmet medical need in Dravet Syndrome and Lennox Gastaut and refractory seizures, a small subset of core prescribers, and the experience of CCO Julian Gangoli. PRICE ACTION: In morning trading, shares of GW Pharmaceuticals have slipped about 1% to $131.90.

GWPH GW Pharmaceuticals
$133.10

-0.35 (-0.26%)

10/04/16
LEER
10/04/16
INITIATION
Target $162
LEER
Outperform
GW Pharmaceuticals reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of GW Pharmaceuticals with an Outperform rating and $162 price target.
10/07/16
GSCO
10/07/16
INITIATION
Target $189
GSCO
Buy
GW Pharmaceuticals initiated with a Buy at Goldman
Goldman analyst Salveen Richter initiated GW Pharmaceuticals with a Buy saying he expects a solid launch trajectory for lead assets Epidiolex for Dravet Syndrome and Lennox-Gastaut Syndrome, two severe orphan epilepsies, and is modeling $1.6B in world-wide sales. Richter has a $189 price target on shares based on a blend of discounted cash flow for $161 per shares and M&A value of $349 per share.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/07/16
10/07/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zillow (ZG, Z) initiated with a Buy at Needham. 2. AMD (AMD) initiated with an Equal Weight at Barclays. 3. Aflac (AFL) was initiated with an Underperform at Credit Suisse while the firm also initiated Prudential (PRU) and Assurant (AIZ) with a Neutral. 4. Fifth Third (FITB) initiated with a Neutral at Wedbush. 5. GW Pharmaceuticals (GWPH) initiated with a Buy at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

13:56
04/28/17
04/28
13:56
04/28/17
13:56
General news
Stocks remain in narrow range »

Stocks are generally…

13:55
04/28/17
04/28
13:55
04/28/17
13:55
General news
Action Economics Survey results: »

Action Economics Survey…

T

AT&T

$39.69

-0.22 (-0.55%)

13:52
04/28/17
04/28
13:52
04/28/17
13:52
Hot Stocks
AT&T invested nearly $7.2B in California wireless and wired networks »

AT&T invested nearly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

  • 16

    May

  • 17

    May

LL

Lumber Liquidators

$24.50

0.14 (0.57%)

13:51
04/28/17
04/28
13:51
04/28/17
13:51
Options
Bullish earnings play in Lumber Liquidators »

Bullish earnings play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

QCOM

Qualcomm

$53.21

0.17 (0.32%)

, AAPL

Apple

$143.79

0.11 (0.08%)

13:50
04/28/17
04/28
13:50
04/28/17
13:50
Recommendations
Qualcomm, Apple analyst commentary  »

Oppenheimer doesn't…

QCOM

Qualcomm

$53.21

0.17 (0.32%)

AAPL

Apple

$143.79

0.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 08

    May

SPY

SPDR S&P 500 ETF Trust

$238.16

-0.44 (-0.18%)

, IVV

iShares Core S&P 500

$239.68

-0.41 (-0.17%)

13:46
04/28/17
04/28
13:46
04/28/17
13:46
Technical Analysis
On The Fly: ETF fund flow highlights »

Per data from ETF.com,…

SPY

SPDR S&P 500 ETF Trust

$238.16

-0.44 (-0.18%)

IVV

iShares Core S&P 500

$239.68

-0.41 (-0.17%)

VOO

Vanguard S&P 500 ETF

$218.65

-0.37 (-0.17%)

IWM

iShares Trust Russell 2000 Index Fund

$139.61

-1.34 (-0.95%)

QQQ

PowerShares QQQ Trust

$135.75

0.81 (0.60%)

XLF

Financial Select Sector

$23.62

-0.145 (-0.61%)

IEMG

iShares Core MSCI Emerging Markets

$48.67

0.065 (0.13%)

EZU

iShares MSCI Eurozone ETF

$39.33

0.0493 (0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$122.08

-0.04 (-0.03%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.16

0.01 (0.01%)

XLP

Consumer Staples Sector SPDR

$55.11

-0.09 (-0.16%)

VNQ

Vanguard REIT Index Fund

$82.86

-0.8037 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPN

Calpine

$10.00

0.41 (4.28%)

13:31
04/28/17
04/28
13:31
04/28/17
13:31
Options
Calpine calls active after earnings »

Calpine calls active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:30
04/28/17
04/28
13:30
04/28/17
13:30
General news
NY Fed accepted $181.98 B in daily reverse repos »

NY Fed accepted $181.98 B…

ALDR

Alder Biopharmaceuticals

$21.35

-0.8 (-3.61%)

13:25
04/28/17
04/28
13:25
04/28/17
13:25
Hot Stocks
Alder Biopharmaceuticals presents 'positive' Phase 2b data for Eptinezumab »

Alder BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

OCN

Ocwen

$2.26

0.03 (1.35%)

13:22
04/28/17
04/28
13:22
04/28/17
13:22
Periodicals
CFPB was seeking Ocwen settlement in $50M range, IMF reports »

The Consumer Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 24

    May

BCEI

Bonanza Creek

$0.79

0.0099 (1.27%)

13:21
04/28/17
04/28
13:21
04/28/17
13:21
Hot Stocks
Breaking Hot Stocks news story on Bonanza Creek »

Bonanza Creek trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:17
04/28/17
04/28
13:17
04/28/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
04/28/17
04/28
13:16
04/28/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAN

Banco Santander

$6.53

0.08 (1.24%)

13:16
04/28/17
04/28
13:16
04/28/17
13:16
Options
Banco Santander put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
04/28/17
04/28
13:15
04/28/17
13:15
General news
Energy Action: Baker-Hughes »

Energy Action:…

BCEI

Bonanza Creek

$0.79

0.0099 (1.27%)

13:10
04/28/17
04/28
13:10
04/28/17
13:10
Hot Stocks
Bonanza Creek announces emergence from Chapter 11 bankruptcy »

Bonanza Creek Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:06
04/28/17
04/28
13:06
04/28/17
13:06
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 4/28 Baker-Hughes…

MSI

Motorola Solutions

$85.88

-0.19 (-0.22%)

13:04
04/28/17
04/28
13:04
04/28/17
13:04
Hot Stocks
Motorola Solutions: ITC to probe unfair trade practices by Hytera »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 31

    May

BCEI

Bonanza Creek

$0.79

0.0049 (0.63%)

13:03
04/28/17
04/28
13:03
04/28/17
13:03
Hot Stocks
Breaking Hot Stocks news story on Bonanza Creek »

Bonanza Creek trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHI

Baker Hughes

$59.34

-0.31 (-0.52%)

13:03
04/28/17
04/28
13:03
04/28/17
13:03
Hot Stocks
Baker Hughes reports U.S. rig count up 13 to 870 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBP

Huttig Building Products

$9.03

0.28 (3.20%)

13:01
04/28/17
04/28
13:01
04/28/17
13:01
Hot Stocks
Huttig Building announces national distribution pact with Knauf Insulation »

Huttig Building Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

13:00
04/28/17
04/28
13:00
04/28/17
13:00
General news
Breaking General news story  »

Federal Reserve Board of…

HNHPF

Hon Hai Precision

12:59
04/28/17
04/28
12:59
04/28/17
12:59
Periodicals
Foxconn to invest in U.S., Reuters reports »

Terry Gou, chairman of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$106.48

-0.015 (-0.01%)

12:51
04/28/17
04/28
12:51
04/28/17
12:51
Options
$7.7M vote of confidence in iShares 7 to 10 year Treasury Bond ETF »

$7.7M vote of confidence…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPN

Calpine

$9.95

0.3599 (3.75%)

12:48
04/28/17
04/28
12:48
04/28/17
12:48
Periodicals
Calpine viewed as potential leveraged buyout target, SparkSpread says »

Comments from Calpine CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.